How Tim Cook made Apple one of the world's most valuable companies - ABC7 Bay Area

HIV TreatmentOctober 11, 2026TheBodyPro | Expert analysis from Benjamin Young, M. D., Ph. D. In a year highlighted by new antiretroviral approvals and often dominated by conversations about simplifying therapy, new study results on the treatment of multidrug-resistant HIV may feel anachronistic. But in a way, the findings — which focus on real-world outcomes of people taking fostemsavir — may be perfectly timed to remind us how complicated HIV treatment strategy still is for an important subset of our patients. Key TakeawaysFostemsavir’s use case remains niche, but it continues to show its value in patients with multidrug resistance and persistent viremia. And its potential immunologic benefits are worth further exploration. At 12 months after initiating fostemsavir-containing treatment, 22% of initially viremic participants achieved HIV RNA below 50 copies/mL, while 59% reached below 200 copies/mL. Among participants already virally suppressed when starting fostemsavir, 79% maintained HIV RNA below 50 copies/mL at 12 months. Read the full analysis here. Further reading:Infectious Disease Advisor | Long-term data support dolutegravir-, fostemsavir-based regimens in MDR HIV-1